Michael Latwis

RealMoney.com Contributor

Michael Latwis directed health care content at TheStreet.com Professional Products. He also has worked at Barclays Wealth management division and was previously associated with Lazard Freres and Fiduciary Trust. Latwis covered companies in the pharmaceutical and specialty pharmaceutical sectors as well as biotech, medical technology, healthcare services, retail and media stocks. He has an MBA from Pace University.

Michael Latwis
By This Author:
« Back
Page 1 of 7
Article

Risks Remain for Endo (RealMoney.com $)

By Michael Latwis

A lack of pipeline confidence could keep its valuation at a discount to peers.

01:25PM 01/09/07

Article

Deals Boost Exelixis' Prospects (RealMoney.com $)

By Michael Latwis

Two new deals solidify the company's research financing and cash position.

07:13AM 01/05/07

Article

Rethinking the Case for Lilly (RealMoney.com $)

By Michael Latwis

I'm still generally bullish on it, but my expectations have been deflated by recent developments.

03:12PM 12/28/06

Article

Troubling Trends at PDL BioPharma

By Michael Latwis

Several pillars of growth are starting to fade at PDL BioPharma.

11:43AM 12/22/06

Article

Keep Par Pharma on the Watch List (RealMoney.com $)

By Michael Latwis

It's still risky but may get more investible in early 2007.

07:59AM 12/19/06

Article

Charles River Getting Back on Course

By Michael Latwis

After an uneven year, positive guidance looks to give the company a boost.

03:37PM 12/15/06

Article

Charles River Getting Back on Course (RealMoney.com $)

By Michael Latwis

After an uneven year, positive guidance looks to give the company a boost.

03:06PM 12/14/06

Article

Beauty Stock Shakeout

By Michael Latwis

Several product rollouts should prove to separate the winners and losers in this sector.

07:35AM 12/13/06

Article

Beauty Stock Shakeout (RealMoney.com $)

By Michael Latwis

Several product rollouts should prove to separate the winners and losers in this sector.

02:01PM 12/12/06

Article

Mixed Outlook for Stent Makers (RealMoney.com $)

By Michael Latwis

Here's how things are shaping up for the major players.

03:23PM 12/11/06

« Back
Page 1 of 7
Dow Jones S&P 500 NASDAQ 10-Year Note
10,023.42 1,069.30 2,112.44 35.03
Oil *
76.05
UP
17.46
UP
2.67
UP
7.12
DOWN
0.30
10 Yr
3.50%
SPDR Gold
107.43
+0.17%
+0.25%
+0.34%
-0.85%
Data delayed 20 minutes

Brokerage Partners